Saratoga Research & Investment Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$64.6M Buy
53,862
+7,337
+16% +$7.5M 3.53% 11
2026
Q1
$42.8M Sell
46,525
-1,630
-3% -$1.65M 2.43% 17
2025
Q4
$51.8M Sell
48,155
-13,304
-22% -$12.7M 2.71% 14
2025
Q3
$46.9M Buy
61,459
+24,226
+65% +$18M 2.44% 15
2025
Q2
$29M Buy
37,233
+6,797
+22% +$5.28M 1.55% 21
2025
Q1
$25.1M Sell
30,436
-871
-3% -$725K 1.33% 25
2024
Q4
$24.2M Buy
+31,307
New +$25.9M 1.22% 26

Other funds holding LLY

Saratoga Research & Investment Management's LLY Position: Q2 2026 in Review

Saratoga Research & Investment Management increased its Eli Lilly (LLY) stake by 16% in Q2 2026, buying an estimated $7.5M and bringing the position to 53,862 shares worth $64.6M. The position accounts for 3.53% of the portfolio, ranked #11.

Saratoga Research & Investment Management first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 3,043 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Saratoga Research & Investment Management held 53,862 shares of Eli Lilly worth $64.6M as of Q2 2026.
  • Saratoga Research & Investment Management bought 7,337 Eli Lilly shares in Q2 2026, an estimated $7.5M.
  • Eli Lilly made up 3.53% of Saratoga Research & Investment Management's portfolio in Q2 2026, its #11 holding.
  • Saratoga Research & Investment Management first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 3,043 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Saratoga Research & Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.